PDCD1LG2 and breast carcinoma: MiR-93 has been implicated as a potential immune regulator in breast cancer cells through targeting programmed death-ligand 1 (PD-L1)/cluster of differentiation 274 (CD274), programmed Cell Death 1 Ligand 2 (PDCD1LG2), and natural killer cell cytotoxicity receptor 3 ligand 1 (NCR3LG1) [42].